These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 15134972

  • 1. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ, Mangold LA, Epstein JI, Partin AW.
    Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
    [Abstract] [Full Text] [Related]

  • 2. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK, Hong SK, Byun SS, Lee SE.
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [Abstract] [Full Text] [Related]

  • 3. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA.
    Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
    [Abstract] [Full Text] [Related]

  • 4. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Oct; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 5. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [Abstract] [Full Text] [Related]

  • 6. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
    Zhu H, Roehl KA, Antenor JA, Catalona WJ.
    Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC, Hovey R, Carroll PR, Shinohara K.
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
    Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE.
    J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
    [Abstract] [Full Text] [Related]

  • 11. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL.
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [Abstract] [Full Text] [Related]

  • 12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW.
    J Urol; 2002 Jul 01; 168(1):100-4. PubMed ID: 12050500
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb 01; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.